Seroatlas · Human Serome Atlas

BMF

Bcl-2-modifying factor

Also known as: BMF_HUMAN, FLJ00065

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q96LC9
Gene: BMF
Ensembl: ENSG00000104081
Chromosome: 15
Canonical length: 184 aa
Protein class: Predicted intracellular proteins
Subcellular location: Cytosol

OverviewNCBI Gene

The protein encoded by this gene belongs to the BCL2 protein family. BCL2 family members form hetero- or homodimers and act as anti- or pro-apoptotic regulators that are involved in a wide variety of cellular activities. This protein contains a single BCL2 homology domain 3 (BH3), and has been shown to bind BCL2 proteins and function as an apoptotic activator. This protein is found to be sequestered to myosin V motors by its association with dynein light chain 2, which may be important for sensing intracellular damage and triggering apoptosis. Alternatively spliced transcript variants encoding different isoforms have been identified. [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

184 residues, UniProt reviewed canonical sequence.

>Q96LC9|BMF
     1  MEPSQCVEEL EDDVFQPEDG EPVTQPGSLL SADLFAQSLL DCPLSRLQLF PLTHCCGPGL
    61  RPTSQEDKAT QTLSPASPSQ GVMLPCGVTE EPQRLFYGNA GYRLPLPASF PAVLPIGEQP
   121  PEGQWQHQAE VQIARKLQCI ADQFHRLHVQ QHQQNQNRVW WQILLFLHNL ALNGEENRNG
   181  AGPR

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against BMF can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Cell surface
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.66
Highest tissue expression: 71 nTPM

Expression across tissuesHPA

Tissue

thymus: 71 nTPM
bone marrow: 31 nTPM
small intestine: 22 nTPM
tonsil: 22 nTPM
duodenum: 20 nTPM
spleen: 18 nTPM

Single-cell type

kupffer cells: 46 nCPM
tuft cells: 35 nCPM
plasma cells: 34 nCPM
thymocytes: 20 nCPM
b-cells: 18 nCPM
monocytes: 17 nCPM

Immune cell

non-classical monocyte: 4 nTPM
neutrophil: 3.2 nTPM
intermediate monocyte: 2.9 nTPM
memory B-cell: 2.9 nTPM
classical monocyte: 2.6 nTPM
eosinophil: 2.5 nTPM

Brain region

white matter: 14 nTPM
thalamus: 11 nTPM
medulla oblongata: 9.8 nTPM
pons: 9.4 nTPM
choroid plexus: 8.9 nTPM
hypothalamus: 8.4 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.01
gnomAD pLI: 0.01
gnomAD missense Z: 0.54
DepMap mean gene effect: -0.32
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Cellular components

Protein domainsUniProt · Pfam · InterPro

Bcl-2-modifying factor
Bcl-2-modifying factor, apoptosis

KeywordsUniProt

Apoptosis

InteractionsUniProt · HPA

Protein binding partners of BMF in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads BMF as an antibody target. Whether an autoantibody or antibody against BMF could matter depends on whether native BMF is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

BMF is annotated at the cell surface, where native BMF is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label BMF as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...